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Peritoneal dialysis related infections: challenges ahead
E d i t o r i a l
Continuous ambulatory peritoneal dialysis (CAPD) is
now a standard therapeutic modality of end-stage renal
disease (ESRD) (1). About 80% of ESRD patients in
Hong Kong are treated by CAPD. Peritoneal dialysis
(PD) related infections, notably peritonitis, are major
complications leading to patient morbidity, mortality and
technique failure. In this issue, we have two papers
addressing these problems (2,3).
A recent systematic review of randomized controlled
trials showed that although there had been a lot of
improvements with peritonitis rate after the advent of
connectology device, mainly disconnect system, the
peritonitis rate remained at one episode per 24 to 34
patient-months using double bag system (4). Our own
Hong Kong multi-center data on 111 patients also showed
that double bag can achieve a peritonitis rate of 33.5
patient-months per episode with exit site infections (ESI)
of 17.4 patient-months per episode (5). There were a trend
of more gram-positive peritonitis in Y-set (52%) than
double-bag (32%), compatible with the hypothesis that
double-bag system reduces the risk of contamination
during spiking procedures (5). However, the beneficial
effect was offset by slightly more gram-negative
peritonitis in double-bag system (32% in double-bag vs
16% in Y-set). As a matter of fact, Pseudomonas account
for 10.7% of all bacterial peritonitis in that study (5).
Piraino et al (6) found that Pseudomonas aeruginosa
replaced Staphylococcus epidermidis as the second most
common cause of catheter infections in the patients using
the Y-set. The number of catheters that had to be removed
due to catheter infections, mainly those due to
Staphylococcus aureus or P. aeruginosa, was the same
in the Y-set and in control groups and they concluded
that the Y-set system is associated with reduced numbers
of catheter infections, but that catheter loss from catheter
infections remains a serious problem. Thus we have been
successfully reducing the peritonitis rate but are still
bothered by the severe ones that are more difficult to
treat and with more complications.
One of the risk factors for peritonitis is ESI. Toronto
group reported their experience of 467 patients out of
whom 19 had P. aeruginosa exit site and tunnel
infections. Out of these 19 patients, 12 had to be treated
with systemic antibiotics (7). Only one of the 12 patients
with P. aeruginosa exit site and tunnel infections treated
with antibiotics resolved; the remaining 11 patients
developed P. aeruginosa peritonitis over a 1-month to
7-month period. One recent local data also found that
the prevalence of ESI was 55% in the review of 353
CAPD patients (8). A total of 131 episodes (range 1-5)
of P. aeruginosa ESI occurred in 78 (40.2%) of the 194
patients who experienced ESI (8). Leung et al (2) in this
issue's Nursing Section reported their retrospective
experience using vinegar together with an oral antibiotics
(ciprofloxacin in this regimen) and found a very good
response rate when compared with their previous
experience using 0.05% aqueous chlorhexidine or eusol
as cleansing agents. The incidence of relapse is also very
low. This has potential implication towards a better
management of P. aeruginosa ESI though a prospective
study is needed to confirm the results.
Apart from ESI and tunnel infections, peritonitis is
obviously another major problem complicating PD and
its treatment poses a major challenge to nephrologists.
The recent International Society of Peritoneal Dialysis
guidelines on PD related peritonitis recommended the
empiric initial use of cefazolin or cephalothin together
with ceftazidime or aminoglycoside if there is no renal
function (9). Alternate use of aminoglycoside is not re-
commended if there is residual renal function. This is in
the light of the problem associated with the non-
discriminate use of vancomycin causing vancomycin-
resistant infections so that vancomycin is not
recommended as initial empiric therapy (10). During a
recent 2-year prospective cohort study in USA (11), rectal
swabs obtained from patients at the beginning and end
of the study period and during interim hospitalizations
were cultured for vancomycin-resistant enterococcus
(VRE). Sixteen of 90 patients (17.8%) became colonized
with VRE, an incidence rate of one case per 9.8 patient-
years of follow-up. Of the 29 patients who did not receive
vancomycin, none have developed VRE compared with
26% of those treated with vancomycin (11). The recent
incidences of VRE discovered in our dialysis patients in
Hong Kong showed that this problem needed to be
addressed and actively prevented. Qi et al (3) in this issue
published their retrospective analysis of using first-
generation cephalosporin plus tobramycin versus
vancomycin plus an aminoglycoside. The primary
response rates were 70.2% for the former and 76.7% for
the latter regime respectively. As the authors used
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vancomycin plus amikacin for more severe peritonitis,
it might favor a better response rate in the cephalosporin
group as they are used for probably milder cases.
Nevertheless, this illustrates the fact that initial empiric
regimen without vancomycin can be quite effective. On
the other hand, the potential problems of resistance,
ototoxicity and damage of residual renal function
associated with aminoglycoside have to be borne in mind
and other regimens without aminoglycoside and
vancomycin need to be developed (12).
The challenges ahead are to reduce the incidence of
peritonitis of the more serious pathogens like S. aureus,
Pseudomonas and fungi. New dialysate with a neutral
pH and bicarbonate buffered may provide a better
environment for peritoneal defense against various
micro-organisms. The study by Cardiff Group recently
suggested that patients continuously exposed to
bicarbonate- and bicarbonate/lactate-buffered PD fluid
might have better-preserved peritoneal macrophage
function and thus improved host defense status (13).
More effective antibiotics towards these "serious"
organisms especially Pseudomonas need to be developed
as peritonitis caused by them can lead to a higher
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